Pharma News, Research & Solutions CSR News

Harris Poll Survey Offers Insights into Potential of Telepsychiatry During and After the COVID-19 Pandemic

A Majority of Respondents Managing Mental Health Conditions Welcome Telepsychiatry Option to Support Continuity of, and Access to, Mental Health Care
Article

As the use of telehealth services has expanded during the COVID-19 pandemic, results from a survey conducted by The Harris Poll showed that more than one in four (27%) U.S. adults surveyed were currently using telepsychiatry (“telepsych”) services for mental health care.

Department of Defense Study Finds Risk of Exposure To COVID-19 Is Almost Non-Existent on United Flights

Multimedia with summary

The results are in: Your risk of exposure to COVID-19 is almost non-existent on our flights (yes, even on a full flight). 

Learn more about the robotic mannequins, biodefense sensors and the results of this U.S. Department of Defense study here.

About United

Medtronic Donates Nearly $1 Million in Personal Protective Equipment to International Medical Corps for COVID-19 Response Efforts

In Partnership with the Medtronic Foundation, More Than 400,000 KN95 Respirators and 1.1 Million Surgical Masks to be Distributed to Healthcare Facilities Across Continental U.S. and Puerto Rico
Press Release

DUBLIN, October 9, 2020 /3BL Media/ - Medtronic, the global leader in medical technology, today announced that it has donated nearly $1 million worth of personal protective equipment (PPE) to relief organization International Medical Corps to support its ongoing COVID-19 response efforts in the continental United States and Puerto Rico.

Johnson & Johnson Joins Other Companies in Signing a Landmark Communiqué on Expanded Global Access for COVID-19

Summary: 

In signing the communiqué, Johnson & Johnson and 15 other life science companies are committing to prioritize the safety, science and accessibility of the potential vaccines, therapeutic medicines or diagnostic tools they are developing to help fight the pandemic.

Article

In signing the communiqué, Johnson & Johnson and 15 other life science companies are committing to prioritize the safety, science and accessibility of the potential vaccines, therapeutic medicines or diagnostic tools they are developing to help fight the pandemic.

The Impact of COVID-19 on a Company: 6 Questions for the Chief Financial Officer of Johnson & Johnson

By Liz Ozaist, Global Content Lab Editor-in-Chief, Johnson & Johnson
Summary: 

When you're the CFO of a company, you have a holistic view of how a pandemic can touch every aspect of a business, especially when it's a healthcare company. So we posed inquiring mind questions to Joe Wolk about what the past eight months have been like for him at the financial helm of the company—via a Zoom interview.

Blog

When you're the CFO of a company, you have a holistic view of how a pandemic can touch every aspect of a business, especially when it's a healthcare company. So we posed inquiring mind questions to Joe Wolk about what the past eight months have been like for him at the financial helm of the company—via a Zoom interview.

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate

First participants dosed in Phase 3 trial (ENSEMBLE) evaluating safety and efficacy of Janssen’s COVID-19 vaccine candidate, JNJ-78436735, also known as Ad26.COV2.S
Press Release

NEW BRUNSWICK, N.J., September 28, 2020 – Johnson & Johnson (NYSE: JNJ) (the Company) recently announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies. The initiation of the ENSEMBLE trial follows positive interim results from the Company’s Phase 1/2a clinical study, which demonstrated that the safety profile and immunogenicity after a single vaccination were supportive of further development.

The Next Phase of Our COVID-19 Vaccine Development

by Alex Gorsky Chairman of the Board and Chief Executive Officer, Johnson & Johnson
Blog

It’s hard to believe that just six months have passed since our scientists identified Janssen’s lead COVID-19 vaccine candidate. We couldn’t have predicted all the changes that have happened since. Two things, however, have been constant: COVID-19 continues to be a devastating pandemic, and Johnson & Johnson has been working around the clock on a potential solution.

The Road to a Vaccine, Season 2, Ep. 7: Is It Really Safe for Schools to Be Open Right Now?

Multimedia with summary

In Season 2 of "The Road to a Vaccine," host Lisa Ling interviews scientists, global health leaders and other experts on the COVID-19 front lines to reveal the latest medical advances and collaborations to create a coronavirus vaccine—and hopefully a return to a world without the pandemic.

As schools reopen—and sometimes close again—what have we learned about the risks of in-person learning? Lisa Ling speaks to school nurse Robin Cogan and pediatrician Dr. Sam Maldonado to find answers and debunk myths around kids and COVID-19.

The Road to a Vaccine, Season 2, Ep. 6: Everything You Need to Know about COVID-19 Testing and Contact Tracing

Multimedia with summary

In Season 2 of "The Road to a Vaccine," host Lisa Ling interviews scientists, global health leaders and other experts on the COVID-19 front lines to reveal the latest medical advances and collaborations to create a coronavirus vaccine—and hopefully a return to a world without the pandemic.

As we head into fall, how is COVID-19 testing going? Lisa Ling speaks to experts, including Ann Lee, co-founder, with actor Sean Penn, of the nonprofit CORE, to get the latest updates on testing efforts and contact tracing across America.

Pages

Subscribe to Pharma News, Research & Solutions